Alentis Therapeutics: Novel mechanisms to treat advanced liver diseases in conjunction with our partner KPMG are proud to invite you to this event featuring Alentis Therapeutics. The Basel based company builds on groundbreaking research from its founder Prof. Thomas Baumert, MD. In 2019 the company seeded by BaseLaunch raised 12.5 million Swiss francs in a series A financing co-lead by BioMedPartners and BB Pureos Bioventures.

Alentis develops first in class drugs that address the growing unmet need in advanced liver diseases such as fatty liver, fibrosis, cirrhosis and liver cancer, now the second leading cause of cancer death worldwide. Changes in lifestyle including obesity are a major driver for the increasing impact of liver disease. Advanced fibrosis is either held steady or gets progressively worse, raising the risk of patients developing liver cancer. Alentis believes it doesn’t have to be that way based on their approach to develop compounds with novel mechanisms of action.

The company explores its proprietary discovery platform that enables identification of novel targets and biomarkers as well as revealing new drug candidates. Its lead compound leverages a previously unknown mechanism of action for fibrosis by targeting a liver cell surface protein which plays are key role in liver disease.

This event will have Dr. Thomas Baumert talking about the story of the company, their plans for the future and their approach to developing therapeutics for liver diseases, as well as a brief introduction on the liver disease space from KPMG.


When: 18.02.2020, 18:30-20:00
Where: Markthalle Basel, Room “Salon”, Steinentorberg 20, 4051 Basel




Door opening


Leonildo Delgado,


Martin Rohrbach, Sector Head Life Sciences KPMG Switzerland
Nicolas Gimenez-Stamminger & Hans Mies, KPMG Switzerland


Alentis Therapeutics: Novel mechanisms to treat advanced lived diseases
Thomas Baumert MD, Professor of Medicine and Institute Head, Université de Strasbourg, founder Alentis




Networking Apero


Participation to the event is free of charge; however, your registration by 17th February 2020 is kindly required.


About the speaker

Thomas Baumert is the scientific founder of Alentis. He holds a chair in hepatology at the University of Strasbourg and is head of the Inserm Institute for Viral and Liver Disease. He is a physician scientist with 25+ years experience in translational research in liver disease.

Prior to Strasbourg Thomas held positions at the Massachusetts General Hospital, Harvard Medical School, the US National Institutes of Health, the Broad Institute and the University Hospitals of Freiburg and Munich. He is an inventor on 15 patent families and the author of 300+ publications. He holds multiple international scientific awards, and is a recipient of the Prix Galien for drug discovery.

Thomas undertook research and clinical training at German Cancer Research Center, Heidelberg; University of Munich; Gastrointestinal Unit, Massachusetts General Hospital, Boston; US National Institutes of Health, NIDDK Liver Disease Branch, Bethesda. He is a board-certified gastroenterologist and internist and has an MD from the University of Heidelberg.


Thank you to our Partner